Geron (GERN) Stock Price, News & Analysis

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1-year target prices for Geron's shares. Their GERN share price targets range from $5.00 to $6.00. On average, they expect the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for GERN or view top-rated stocks among Wall Street analysts.

Geron's stock was trading at $2.11 at the start of the year. Since then, GERN stock has increased by 75.4% and is now trading at $3.70.
View the best growth stocks for 2024 here.

Geron saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 46,660,000 shares, a decrease of 8.4% from the March 15th total of 50,950,000 shares. Based on an average trading volume of 11,240,000 shares, the days-to-cover ratio is presently 4.2 days.
View Geron's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GERN earnings forecast.

Geron Co. (NASDAQ:GERN) issued its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. Geron had a negative trailing twelve-month return on equity of 63.33% and a negative net margin of 77,691.14%. The firm's revenue for the quarter was down 77.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.10) earnings per share.

ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Loncar China Biopharma ETF (CHNA), WisdomTree BioRevolution Fund (WDNA), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Range Cancer Therapeutics ETF (CNCR), SPDR S&P Biotech ETF (XBI) and Invesco Nasdaq Future Gen 200 ETF (QQQS).

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

Geron's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.06%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis.
View institutional ownership trends.

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.